SG11201909361SA - Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells - Google Patents

Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells

Info

Publication number
SG11201909361SA
SG11201909361SA SG11201909361SA SG11201909361SA SG 11201909361S A SG11201909361S A SG 11201909361SA SG 11201909361S A SG11201909361S A SG 11201909361SA SG 11201909361S A SG11201909361S A SG 11201909361SA
Authority
SG
Singapore
Prior art keywords
international
october
mucopolysaccharidosis
sulfatase
ids
Prior art date
Application number
Inventor
Stephen Yoo
Rickey Reinhardt
Curran Simpson
Zhuchun Wu
Original Assignee
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc filed Critical Regenxbio Inc
Publication of SG11201909361SA publication Critical patent/SG11201909361SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

ITR Chicken -actin intron tintglifiditionat&. Cytomegalovirus Immediate-early enhancer Chicken p-actin promoter Rabbit p- globin poly A signal FIG. 5 ITR (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT 0111111010 0111 °nolo mu Oil IIIII Kuno oimIE (10) International Publication Number WO 2018/191666 Al (51) International Patent Classification: A61K 38/43 (2006.01) A61P 25/00 (2006.01) A61K 47/26 (2006.01) Cl 2N 15/86 (2006.01) A61K 48/00 (2006.01) (21) International Application Number: PCT/US2018/027568 (22) International Filing Date: 13 April 2018 (13.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/485,659 14 April 2017 (14.04.2017) US 62/573,921 18 October 2017 (18.10.2017) US 62/574,355 19 October 2017 (19.10.2017) US 62/579,686 31 October 2017 (31.10.2017) US (71) Applicant: REGENXBIO INC. [US/US]; 9712 Medical Center Drive, Suite 100, Rockville, MD 20850 (US). (72) Inventors: YOO, Stephen; 5521 Southwick Street, Bethes- da, MD 20817 (US). REINHARDT, Rickey, Robert; 108 Apple Grove Road, Silver Spring, MD 20904 (US). SIM- PSON, Curran, Matthew; 2149 Thurston Road, Frederick, MD 21704 (US). WU, Zhuchun; 14716 Soft Wind Drive, North Potomac, MD 20878 (US). (74) Agent: ELBERT, Maya et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2 SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS CB7 promoter (57) : Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
SG11201909361S 2017-04-14 2018-04-13 Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells SG11201909361SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762485659P 2017-04-14 2017-04-14
US201762573921P 2017-10-18 2017-10-18
US201762574355P 2017-10-19 2017-10-19
US201762579686P 2017-10-31 2017-10-31
PCT/US2018/027568 WO2018191666A1 (en) 2017-04-14 2018-04-13 Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells

Publications (1)

Publication Number Publication Date
SG11201909361SA true SG11201909361SA (en) 2019-11-28

Family

ID=63793615

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909361S SG11201909361SA (en) 2017-04-14 2018-04-13 Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells

Country Status (12)

Country Link
US (1) US11613739B2 (en)
EP (1) EP3609526A4 (en)
JP (2) JP2020516291A (en)
KR (1) KR20190139951A (en)
AU (1) AU2018253303A1 (en)
BR (1) BR112019021569A2 (en)
CA (1) CA3059441A1 (en)
IL (2) IL269892B2 (en)
SG (1) SG11201909361SA (en)
TW (1) TW201903146A (en)
UY (1) UY37679A (en)
WO (1) WO2018191666A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021569A2 (en) 2017-04-14 2020-05-12 Regenxbio Inc. PRECURSOR OF GLUCOSYLATED RECOMBINANT HUMAN IDURONATE-2-SULPHATASE (IDS), METHOD FOR TREATING A HUMAN SUBJECT DIAGNOSED WITH TYPE II MUCOPOLYSACARIDOSIS (MPS II)
CN110960671A (en) * 2019-12-25 2020-04-07 广州中医药大学(广州中医药研究院) New application of Elabela polypeptide and medicine thereof
KR20220148162A (en) * 2020-01-29 2022-11-04 리젠엑스바이오 인크. Treatment of Mucopolysaccharidosis II with Recombinant Human Iduronate-2-sulfatase (IDS) Produced by Human Neuronal or Glia Cells
AU2022214429A1 (en) 2021-02-01 2023-09-14 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
KR20230145386A (en) * 2021-02-10 2023-10-17 리젠엑스바이오 인크. Treatment of mucopolysaccharidosis II using recombinant human iduronate-2-sulfatase (IDS)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2369002A1 (en) 1999-08-09 2011-09-28 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
EP1453547B1 (en) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
CN1856576B (en) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
CN104293835B (en) 2005-04-07 2017-07-04 宾夕法尼亚大学托管会 The method for strengthening function of gland related viral vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
ES2754234T3 (en) * 2010-06-25 2020-04-16 Shire Human Genetic Therapies Methods and compositions for CNS administration of iduronate-2-sulfatase
CN107828820B (en) 2010-10-27 2022-06-07 学校法人自治医科大学 Adeno-associated virus particles for gene transfer into nervous system cells
DK2673289T3 (en) 2011-02-10 2023-07-24 Univ North Carolina Chapel Hill VIRUS VECTORS WITH MODIFIED TRANSDUCTION PROFILES AND METHODS FOR THEIR PRODUCTION AND USE
LT3693025T (en) 2011-04-22 2022-02-10 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
KR101158673B1 (en) 2011-06-24 2012-07-03 주식회사 지씨바이오 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
EP3147295B2 (en) 2011-08-24 2023-11-22 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
WO2014160092A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
MX2015015560A (en) * 2013-05-15 2016-06-17 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system.
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
CN116574158A (en) 2013-10-11 2023-08-11 马萨诸塞眼科耳科诊所 Method for predicting ancestral virus sequence and use thereof
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
JP6605482B2 (en) * 2014-02-19 2019-11-13 バイオアシス テクノロジーズ インコーポレイテッド P97-IDS fusion protein
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US20170191041A1 (en) * 2014-07-11 2017-07-06 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
EP3218000A2 (en) * 2014-11-10 2017-09-20 Alexion Pharmaceuticals, Inc. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
MA41198A (en) * 2014-12-18 2017-10-24 Shire Human Genetic Therapies ENZYMATIC ACTIVITY TESTS FOR I2S
WO2016126729A1 (en) 2015-02-03 2016-08-11 Visa International Service Association Validation identity tokens for transactions
HRP20220050T1 (en) * 2015-05-15 2022-10-14 Regents Of The University Of Minnesota Adeno-associated for therapeutic delivery to central nervous system
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
EP3452104A1 (en) * 2016-04-15 2019-03-13 The Trustees of The University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
BR112019021569A2 (en) 2017-04-14 2020-05-12 Regenxbio Inc. PRECURSOR OF GLUCOSYLATED RECOMBINANT HUMAN IDURONATE-2-SULPHATASE (IDS), METHOD FOR TREATING A HUMAN SUBJECT DIAGNOSED WITH TYPE II MUCOPOLYSACARIDOSIS (MPS II)
KR20220148162A (en) 2020-01-29 2022-11-04 리젠엑스바이오 인크. Treatment of Mucopolysaccharidosis II with Recombinant Human Iduronate-2-sulfatase (IDS) Produced by Human Neuronal or Glia Cells

Also Published As

Publication number Publication date
US20200149019A1 (en) 2020-05-14
UY37679A (en) 2018-11-30
US11613739B2 (en) 2023-03-28
IL269892A (en) 2019-12-31
IL307936A (en) 2023-12-01
JP2023052096A (en) 2023-04-11
BR112019021569A2 (en) 2020-05-12
WO2018191666A1 (en) 2018-10-18
AU2018253303A1 (en) 2019-10-31
IL269892B1 (en) 2023-12-01
JP2020516291A (en) 2020-06-11
CA3059441A1 (en) 2018-10-18
EP3609526A1 (en) 2020-02-19
KR20190139951A (en) 2019-12-18
TW201903146A (en) 2019-01-16
EP3609526A4 (en) 2021-01-13
IL269892B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
SG11201909361SA (en) Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
SG11201807002TA (en) Intention signaling for an autonomous vehicle
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201909999RA (en) Linked multiple blockchain system
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201407898WA (en) Electrode testing apparatus
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201906452PA (en) Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
SG11201810161RA (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
SG11201807134RA (en) Transposon system and methods of use
SG11201408261UA (en) Syringe
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201805072PA (en) Nicotine powder delivery system
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201809693SA (en) SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201804721SA (en) Modulators of complement activity
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods